Bridons research contributions include: Development of Drug Affinity Complex (DAC) technology for albumin binding and peptide half-life extension Identification and characterization of CJC-1295 as a long-lasting GRF analog with sustained growth hormone-releasing properties Pioneering work on maleimido-derivatized GHRH analogs and their bioconjugation to serum albumin Demonstration of 4-fold increase in growth hormone area-under-curve with optimized CJC-1295 formulation versus native GHRH Extensive in vitro and in vivo pharmacological characterization in rat and human models His 2005 publication in Endocrinology titled Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog remains the foundational reference for CJC-1295 research, establishing the peptides mechanism of action and pharmacokinetic profile that enabled subsequent clinical investigation

The ghrelin receptor stimulates the secretion (but not synthesis) of stored growth hormone
Glutathione essentially supports tissue regeneration, which is crucial for maintaining elasticity and reducing the appearance of fine lines and wrinkles, says Dr Stefanie Williams, a dermatologist and founder and medical director of Eudelo
The most overlooked error in peptide protocols: injecting air into the vial before drawing the solution
Ipamorelin: 100-300 mcg per injection CJC-1295 (no DAC / mod GRF 1-29): 100-300 mcg per injection Frequency: 1-3 injections daily, subcutaneous, ideally on an empty stomach or 90 minutes after the last meal and before sleep Cycle length: 12-24 weeks followed by a 4-to-8-week break to avoid GH receptor downregulation Injection site: Abdomen, approximately 1-2 inches from the navel, rotating sites each injection The pre-sleep injection is prioritized because it coincides with the largest endogenous GH pulse, which occurs roughly 60-90 minutes after sleep onset and is tied to slow-wave sleep [8]